Surprisingly, however, we found a negative correlation between age and CD8+ TILs and a better response to immune checkpoint therapy in patients with CRC older than 70 years, suggesting that age may be a very important factor in patient prognosis and immunotherapy. The gene discussed is CD8A; the disease is colorectal carcinoma.